Nicolet Bankshares Inc. decreased its stake in shares of Stryker Co. (NYSE:SYK) by 2.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,596 shares of the medical technology company’s stock after selling 75 shares during the quarter. Nicolet Bankshares Inc.’s holdings in Stryker were worth $513,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Blue Fin Capital Inc. grew its position in Stryker by 13.8% during the 3rd quarter. Blue Fin Capital Inc. now owns 7,047 shares of the medical technology company’s stock worth $1,252,000 after purchasing an additional 857 shares during the period. Kentucky Retirement Systems acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $1,831,000. Standard Life Aberdeen plc raised its position in shares of Stryker by 10.9% in the 3rd quarter. Standard Life Aberdeen plc now owns 100,776 shares of the medical technology company’s stock valued at $17,907,000 after acquiring an additional 9,888 shares during the period. Waldron Private Wealth LLC raised its position in shares of Stryker by 16.0% in the 3rd quarter. Waldron Private Wealth LLC now owns 82,118 shares of the medical technology company’s stock valued at $14,590,000 after acquiring an additional 11,315 shares during the period. Finally, Kepos Capital LP raised its position in shares of Stryker by 8.8% in the 3rd quarter. Kepos Capital LP now owns 36,809 shares of the medical technology company’s stock valued at $6,540,000 after acquiring an additional 2,971 shares during the period. Institutional investors and hedge funds own 74.67% of the company’s stock.
In related news, VP Yin C. Becker sold 15,240 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $198.03, for a total value of $3,017,977.20. Following the completion of the transaction, the vice president now directly owns 16,577 shares of the company’s stock, valued at $3,282,743.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP M Kathryn Fink sold 180 shares of the firm’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $176.77, for a total transaction of $31,818.60. The disclosure for this sale can be found here. Insiders sold 130,455 shares of company stock valued at $24,723,292 over the last three months. 7.20% of the stock is owned by company insiders.
Shares of SYK opened at $188.28 on Monday. The company has a market cap of $70.25 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 2.28 and a beta of 0.88. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $199.85. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.41.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The company had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same period last year, the business earned $1.68 EPS. The business’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Co. will post 8.15 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.52 dividend. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a dividend yield of 1.10%. Stryker’s dividend payout ratio is presently 28.45%.
A number of analysts recently issued reports on SYK shares. Deutsche Bank increased their target price on Stryker from $181.00 to $208.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird increased their target price on Stryker from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $209.00 target price for the company in a research note on Thursday. Canaccord Genuity increased their target price on Stryker from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Oppenheimer increased their target price on Stryker from $183.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Seven analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $196.89.
ILLEGAL ACTIVITY WARNING: “Nicolet Bankshares Inc. Sells 75 Shares of Stryker Co. (SYK)” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://transcriptdaily.com/2019/04/29/nicolet-bankshares-inc-sells-75-shares-of-stryker-co-syk.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: What is a trade deficit?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.